Nektar Therapeutics (NKTR)
1.285
-0.04
(-2.65%)
USD |
NASDAQ |
Nov 13, 16:00
1.34
+0.06
(+4.28%)
After-Hours: 20:00
Nektar Therapeutics Revenue (Annual): 90.12M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 90.12M |
| December 31, 2022 | 92.06M |
| December 31, 2021 | 101.91M |
| December 31, 2020 | 152.92M |
| December 31, 2019 | 114.62M |
| December 31, 2018 | 1.193B |
| December 31, 2017 | 307.71M |
| December 31, 2016 | 165.44M |
| December 31, 2015 | 230.78M |
| December 31, 2014 | 200.71M |
| December 31, 2013 | 148.92M |
| December 31, 2012 | 81.19M |
| December 31, 2011 | 71.48M |
| December 31, 2010 | 159.04M |
| December 31, 2009 | 71.93M |
| Date | Value |
|---|---|
| December 31, 2008 | 90.18M |
| December 31, 2007 | 273.03M |
| December 31, 2006 | 217.72M |
| December 31, 2005 | 126.28M |
| December 31, 2004 | 114.27M |
| December 31, 2003 | 106.26M |
| December 31, 2002 | 94.84M |
| December 31, 2001 | 77.47M |
| December 31, 2000 | 51.63M |
| December 31, 1999 | 41.36M |
| December 31, 1998 | 21.80M |
| December 31, 1997 | 16.25M |
| December 31, 1996 | 6.90M |
| December 31, 1995 | 3.40M |
| December 31, 1994 | 1.70M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
90.12M
Minimum
2023
152.92M
Maximum
2020
110.32M
Average
101.91M
Median
2021
Revenue (Annual) Benchmarks
| Eli Lilly and Co | 34.12B |
| Esperion Therapeutics Inc | 116.33M |
| NovaBay Pharmaceuticals Inc | 14.73M |
| Palatin Technologies Inc | 4.490M |
| iBio Inc | 0.225M |